Method for manufacturing pancreatic-hormone-producing cells
| Title: | Method for manufacturing pancreatic-hormone-producing cells |
|---|---|
| Patent Number: | 8,932,853 |
| Publication Date: | January 13, 2015 |
| Appl. No: | 13/520090 |
| Application Filed: | December 28, 2010 |
| Abstract: | The present invention provides a method of more efficiently producing pancreas cells, particularly pancreatic hormone-producing cells, a method of stably producing pancreas cells in a large amount by more efficiently inducing differentiation of stem cells into pancreas cells, a medicament containing a pancreas cells and a screening method using the cells. A method of producing pancreatic hormone-producing cells, including subjecting stem cells to the following steps (1)-(4): (1) a step of cultivating stem cells in a medium containing an activator of activin receptor-like kinase-4,7 and a GSK3 inhibitor (2) a step of cultivating the cells obtained in the aforementioned step (1) in a medium containing an activator of activin receptor-like kinase-4,7 (3) a step of cultivating the cells obtained in the aforementioned step (2) in a medium containing any one or more kinds selected from the group consisting of (a) retinoic acid receptor agonists, (b) at least one kind selected from the group consisting of inhibitors of AMP-activated protein kinase and/or activin receptor-like kinase-2,3,6, and BMP antagonists, and (c) inhibitors of activin receptor-like kinase-4,5,7 (4) a step of cultivating the cells obtained in the aforementioned step (3). |
| Inventors: | Hosoya, Masaki (Kanagawa, JP); Kunisada, Yuya (Kanagawa, JP); Shoji, Masanobu (Kanagawa, JP); Yamazoe, Noriko (Kanagawa, JP) |
| Assignees: | Takeda Pharmaceutical Company Limited (Osaka, JP) |
| Claim: | 1. A method of producing pancreatic hormone-producing cells, comprising: (i) culturing human or mouse induced-pluripotent stem (iPS) cells, in a medium containing an activator of activin receptor-like kinase-4,7 and a GSK3 inhibitor, (ii) culturing the cells of step (i) in a medium containing an activator of activin receptor-like kinase-4,7, (iii) culturing the cells obtained in step (ii) in a medium containing the following (a)-(c): (a) retinoic acid receptor agonists, (b) at least one kind selected from the group consisting of inhibitors of AMP-activated protein kinase and/or activin receptor-like kinase-2,3,6, and BMP antagonists, and (c) inhibitors of activin receptor-like kinase-4,5,7, and (iv) culturing the cells obtained from step (iii) in a medium containing any factor selected from the group consisting of (ia) at least one kind selected from the group consisting of adenylate cyclase activators, cAMP phosphodiesterase inhibitors and cAMP analogs, (ib) steroids and (ic) inhibitors of activin receptor-like kinase-4,5,7 to obtain pancreatic hormone-producing cells. |
| Claim: | 2. The method according to claim 1 , wherein the activator of activin receptor-like kinase-4,7 in steps (i) and (ii) is activin, and step (iii) is a step of culturing the cell(s) obtained in step (ii) in a medium containing any one or more kinds selected from the group consisting of (a) retinoic acid receptor agonists, (b) inhibitors of AMP-activated protein kinase and/or activin receptor-like kinase-2,3,6 and (c) inhibitors of activin receptor-like kinase-4,5,7. |
| Claim: | 3. The method according to claim 1 , wherein the GSK3 inhibitor in step (i) is 6-[[2-[[4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]nicotinonitrile. |
| Claim: | 4. The method according to claim 1 , wherein the inhibitor of activin receptor-like kinase-4,5,7 in step (iii) is 4[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide or a hydrate thereof. |
| Claim: | 5. The method according to claim 1 , wherein said at least one kind selected from the group consisting of inhibitors of AMP-activated protein kinase and/or activin receptor-like kinase-2,3,6, and BMP antagonists in step (iii) is dorsomorphin or Noggin. |
| Claim: | 6. The method according to claim 1 , wherein the medium in step (iii) contains retinoic acid, 4-[4-(1,3-benzodioxl-5-yl)-5(2-pyridinyl)-1H-imidazol-2-yl]-benzamide or a hydrate thereof, and dorsomorphin. |
| Claim: | 7. The method according to claim 1 , wherein at least one kind selected from the group consisting of adenylate cyclase activators, cAMP phosphodiesterase inhibitors and cAMP analogs is forskolin, 3-isobutyl-1-methylxanthine or dibutyl cAMP. |
| Claim: | 8. The method according to claim 1 , wherein the steroid is dexamethasone. |
| Claim: | 9. The method according to claim 1 , wherein the inhibitor of activin receptor-like kinase-4,5,7 is 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, or 4-[4-(1,3-benzodioxol -5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide or a hydrate thereof. |
| Claim: | 10. The method of claim 1 , wherein the medium in step (iv) contains nicotinamide. |
| Current U.S. Class: | 435/325 |
| Patent References Cited: | 5942435 August 1999 Wheeler 6326201 December 2001 Fung et al. 7033831 April 2006 Fisk et al. 7326572 February 2008 Fisk et al. 7534608 May 2009 Martinson et al. 2003/0138948 July 2003 Fisk et al. 2003/0138949 July 2003 Bhushan et al. 2005/0266555 December 2005 Lu et al. 2006/0040387 February 2006 Fisk et al. 2008/0145889 June 2008 Fisk et al. 2008/0207594 August 2008 Mussmann et al. 2009/0093055 April 2009 Fisk et al. 2009/0325180 December 2009 Fisk et al. 2002-538779 November 2002 2006-500003 January 2006 2006-506047 February 2006 2006-075022 March 2006 2009-225661 October 2009 WO-00/47720 August 2000 WO-03/050249 June 2003 WO-03/100026 December 2003 WO-2007/113505 October 2007 WO-2008/015418 February 2008 WO-2008/033408 March 2008 WO-2008/066199 June 2008 WO-2009/012428 January 2009 WO 2009/018453 February 2009 WO-2009/018453 February 2009 WO-2009/070592 June 2009 |
| Other References: | Xu et al., cited on IDS Jun. 29, 2012, reference BA. cited by examiner NIH Adult Stem Cell Guidelines. cited by examiner NIH Embryonc Stem Cell Guidelines. cited by examiner Brevini et al., 2010, Theriogenology, vol. 74, pp. 544-550. cited by examiner Paris et al., 2010, Theriogenology, vol. 74, pp. 516-524. cited by examiner Munoz et al., 2008, Theriogenology, vol. 69, pp. 1159-1164. cited by examiner Hao et al. (2008, PLoS One, vol. 3(8), pp. 1-8). cited by examiner Rafacho et al. (2009, Am. J. Physiol. Endocrinol. Metab., vol. 296, pp. E681-E689). cited by examiner D'Amour et al. (2006, Nature Biotechnology, vol. 24(11), pp. 1392-1401). cited by examiner Wrighton, K.H. et al., Transforming Growth Factor β Can Stimulate SMADL Phosphorylation Independently of Bone Morphogenic Protein Receptors, J. Biol. Chem., 2009, vol. 284, No. 15, p. 9755-9763. cited by applicant Yu, P.B. et al. Dorsomorphin Inhibits BMP Signals Required for Embryogenesis and Iron Metabolism, Nat. Chem. Biol., 2008, vol. 4, No. 1, p. 33-41. cited by applicant Kroon, E. et al., Pancreatic Endoderm Derived From Himan Embryonic Stem Cells Generates Glucose-Responsive Insulin-Secreting Cells in Vivo, Nature Biotech. 26, 2008, p. 443-452. cited by applicant D'Amour, K. et al., Production of Pancreatic Hormone-Expressing Endocrine Cells From Human Embryonic Stem Cells, Nature Biotech. 24, 2006, p. 1392-1401. cited by applicant Jiang, W., et al., In Vitro Derivation of Functional Insulin-Producing Cells From Human Embryonic Stem Cells, Cell Research 17, 2007, p. 333-344. cited by applicant Maehr, R. et al., Generation of Pluripotent Stem Cells From Patients With Type 1 Diabetes, PNAS 106, 2009, p. 15768-15773. cited by applicant Shim, J.H. et al., Directed Differentiation of Human Embryonic Stem Cells Towards a Pancreatic Cell Fate, Diabetologia 50, 2007, p. 1228-1238. cited by applicant Rezania, A., et al., Production of Functional Glucagon-Secreting α-Cells From Human Embryonic Stem Cells, Diabetes 60, 2011, p. 239-247. cited by applicant Kume et al, BMB2010 Biochemistry and Molecular Biology (3P-0861; Abstract). cited by applicant International Search Report from PCT/JP2010/073906. cited by applicant |
| Assistant Examiner: | Montanari, David A |
| Primary Examiner: | Singh, Anoop |
| Attorney, Agent or Firm: | Edwards Wildman Palmer LLP Neuner, George W. |
| Accession Number: | edspgr.08932853 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|